Drug Trial News

RSS

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

First-in-class cancer drug gamitrinib evaluated in phase 1 clinical trial

Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse."

2 Jun 2026

High-risk prostate cancer patients benefit from perioperative apalutamide therapy

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

31 May 2026

Daraxonrasib significantly extends survival in metastatic pancreatic cancer

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

31 May 2026

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients

Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients with advanced stage or recurrent endometrial cancer when compared to chemotherapy alone.

29 May 2026

Teclistamab delivers deeper responses in relapsed myeloma patients

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

29 May 2026

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.

29 May 2026

Ocrelizumab slows disability progression in advanced progressive multiple sclerosis

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows disability progression in people with primary progressive multiple sclerosis (PPMS), including older patients and those with more advanced disease who are wheelchair users.

28 May 2026

Tezepelumab reduces steroid dependence in severe asthma patients

New results from the Phase 3 SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes.

28 May 2026

New study tests vitamin D analog against pancreatic cancer

A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.

26 May 2026

Pioneering cell therapy offers hope for advanced liver disease

A new type of cell therapy shows promise as the first treatment for advanced liver disease, following results from a clinical trial.

25 May 2026

Semaglutide helps patients who gain weight after bariatric surgery

New UCL research supports use of the weight loss drug semaglutide for patients who do not get enough benefit from bariatric surgery.

22 May 2026

Could blocking inflammation help treat difficult-to-treat depression?

A small proof-of-concept RCT found that tocilizumab, an IL-6 receptor blocker, showed a non-significant but clinically suggestive pattern of improvement in difficult-to-treat depression linked to low-grade inflammation. The study found that baseline hs-CRP, rather than IL-6, may help identify patients most likely to respond, supporting larger trials of immune-targeted depression care.

22 May 2026

Oral drug improves platelet recovery during chemotherapy in gastrointestinal cancer patients

An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet recovery and helped patients with gastrointestinal cancers maintain platelet counts needed to continue chemotherapy as scheduled, according to results from a phase 2 clinical trial led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and Mass General Hospital.

21 May 2026

Experimental virus therapy targets resistant high-grade neuroendocrine tumors

A phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors that often resist treatment.

21 May 2026

Phase two clinical trial demonstrates dramatic mobility gains in children with severe fibrous dysplasia

Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, leading to fractures, pain, deformities, and severe mobility impairment. In many patients, diseased bone tissue produces excessive amounts of fibroblast growth factor-23 (FGF23), a hormone that causes phosphate loss through the kidneys.

21 May 2026

Anti-inflammatory drug tocilizumab shows promise for difficult-to-treat depression

Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key finding from a University of Bristol-led pilot randomised controlled clinical trial, published in JAMA Psychiatry today [20 May].

20 May 2026

Stem cell infusions improve symptoms in butterfly skin disease

The intravenous infusion of mesenchymal stem cells from family donors is safe and improves symptoms such as pruritus (itching), sleep disturbances, and fatigue associated with Recessive Dystrophic Epidermolysis Bullosa (RDEB), popularly known as "butterfly skin".

18 May 2026

Azithromycin fails to improve severe wheezing in preschool children

A study led by researchers at the University of Arizona College of Medicine – Tucson showed that giving the antibiotic azithromycin did not help preschool children seen in the hospital emergency room with bouts of severe wheezing.

18 May 2026

Tezepelumab reduces asthma exacerbations in diverse patient population

The drug tezepelumab was shown to significantly reduce exacerbations in people with severe asthma in clinical trials.

18 May 2026

1
2
3
4
...
1166
Next

Drug Trial News

Three-drug strategy forces pancreatic tumors into lasting regression

First-in-class cancer drug gamitrinib evaluated in phase 1 clinical trial

High-risk prostate cancer patients benefit from perioperative apalutamide therapy

Daraxonrasib significantly extends survival in metastatic pancreatic cancer

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients

Teclistamab delivers deeper responses in relapsed myeloma patients

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

Ocrelizumab slows disability progression in advanced progressive multiple sclerosis

Tezepelumab reduces steroid dependence in severe asthma patients

New study tests vitamin D analog against pancreatic cancer

Pioneering cell therapy offers hope for advanced liver disease

Semaglutide helps patients who gain weight after bariatric surgery

Could blocking inflammation help treat difficult-to-treat depression?

Oral drug improves platelet recovery during chemotherapy in gastrointestinal cancer patients

Experimental virus therapy targets resistant high-grade neuroendocrine tumors

Phase two clinical trial demonstrates dramatic mobility gains in children with severe fibrous dysplasia

Anti-inflammatory drug tocilizumab shows promise for difficult-to-treat depression

Stem cell infusions improve symptoms in butterfly skin disease

Azithromycin fails to improve severe wheezing in preschool children

Tezepelumab reduces asthma exacerbations in diverse patient population

Building quality into drug development for safer, faster medicines

Advancing Human Muscle Models for Drug Development and Preclinical Testing

Enhancing reproducibility in genomics workflows

Latest News